
Ultimovacs ASA
OSE:ULTI.OL
116 (NOK) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Ultimovacs ASA |
Symbool | ULTI.OL |
Munteenheid | NOK |
Prijs | 107.4 |
Beurswaarde | 3,694,184,100 |
Dividendpercentage | 0% |
52-weken bereik | 67.9 - 178.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Carlos de Sousa |
Website | https://ultimovacs.com |
An error occurred while fetching data.
Over Ultimovacs ASA
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (NOK)
Cijfers zijn in miljoenen (NOK)